Full Press Release Details
Jaffe Completes $2.7 Million Private Placement of Common Stock
Strengthens Financial Position Ahead of Key Milestones
California - March 13, 2019 - Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical
devices that restore cardiac and vascular health, has closed a private placement of 2,360,051 shares of its common stock for aggregate
gross proceeds of approximately $2.7 million with various accredited investors, including participation by a member of HJLI's
management. Investors did not receive warrants. The company intends to use these proceeds to fund the continued development of
its two lead products and for working capital and general corporate purposes.
advance of key milestones including preliminary data for our VenoValve first in-human study, and our CoreoGraft feasibility
study, we wanted to strengthen our balance sheet and extend our operational runway," said Robert Berman, Hancock Jaffe's
Chief Executive Officer. "We remain confident with our projected timeline for these two major milestones at the end of the
second quarter of 2019, and this financing will insure that we are adequately capitalized through the release of our results."
currently has two lead products: the VenoValve; and the CoreoGraft. The VenoValve addresses a debilitating condition known as
chronic venous insufficiency (CVI), caused by malfunctioning valves in the deep veins of the patient's leg, and often resulting
in swelling, intense pain, and open sores. Approximately 2.4 million people in the U.S. suffer from deep venous CVI due to valvular
incompetence and there are currently no FDA approved treatments for the condition. In February of 2019, Hancock Jaffe implanted
the first VenoValve in a patient in Bogota, Colombia. Patient's receive follow-up assessments 14 days, 30 days, 60 days
and 90 days after implantation. Enrollment for the first-in-human study is ongoing and HJLI will provide an update once additional
patients are enrolled in the study.
CoreoGraft is a potential replacement for saphenous vein grafts (SVGs) commonly used to revascularize the heart during coronary
artery bypass graft (CABG) surgeries. With approximately 200,000 CABG surgeries performed each year in the U.S., CABG surgery
is the most commonly performed cardiac surgical procedure accounting for over 62% of all cardiac surgeries. In addition to the
SVG harvest procedure being painful and prone to complications for the patient, SVGs are known to have significant short-term
and long-term failure rates, restricting needed blood flow to the heart and resulting in symptoms such as chest pain, shortness
of breath, and increased cardiac mortality rates. HJLI is currently conducting a pre-clinical feasibility study for the CoreoGraft
at the world renowned Texas Heart Institute and will provide an update once CoreoGrafts are implanted. Hancock Jaffe expects results
from the study to be released in June of 2019.
the terms of the Private Placement, Hancock Jaffe has agreed to file a registration statement for the resale of the purchasers
shares on Form S-1 on or before March 31, 2019 and to use its commercially reasonable efforts to have the registration statement
declared effective within ninety days of the filing date. The offering was made pursuant to an exemption from the registration
requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"), solely to accredited investors.
Network 1 Financial Securities acted as the exclusive placement agent.
Hancock Jaffe Laboratories, Inc.
Jaffe Laboratories (NASDAQ: HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to
establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product
candidates: the VenoValve , a porcine based valve which is intended to be surgically implanted in the deep venous system of
the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft , a bovine tissue based off the
shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a third product candidate, which is a
porcine tissue based heart valve, which may be a candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe has a
19-year history of developing and producing FDA approved medical devices that sustain or support life. The current management
team at Hancock Jaffe has been associated with over 80 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.
Note on Forward-Looking Statements
press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories,
Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant
risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects,"
"may," "will," "could," "would," "should," "believes," "expects,"
"anticipates," "estimates," "intends," "plans," "potential" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant
risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.
Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical development
activities, including obtaining preliminary data for the Company's VenoValve first in-human study, and the Company's
CoreoGraft feasibility study, described herein) may differ significantly from those set forth or implied in the forward-looking
statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Jaffe Press Contact:
& Investor Relations Contact:
Group - North America